HBIO Harvard Bioscience
- 3.300
- -0.070-2.08%
Harvard Bioscience News
Benchmark Co. Sticks to Their Buy Rating for Harvard Bioscience (HBIO)
Benchmark Reiterates Speculative Buy on Harvard Bioscience, Maintains $7 Price Target
Keybanc Adjusts Price Target on Harvard Bioscience to $7 From $5, Maintains Overweight Rating
Analysts Offer Insights on Healthcare Companies: Biogen (BIIB), Harvard Bioscience (HBIO) and Disc Medicine (IRON)
Keybanc Maintains Overweight on Harvard Bioscience, Raises Price Target to $7
KeyBanc Capital Markets Trims Price Target on Harvard Bioscience to $5 From $7, Maintains Overweight Rating
KeyBanc Reaffirms Their Buy Rating on Harvard Bioscience (HBIO)
Harvard Bioscience Analyst Ratings
Keybanc Maintains Overweight on Harvard Bioscience, Lowers Price Target to $5
KeyBanc Capital Markets Trims Price Target on Harvard Bioscience to $7 From $10, Keeps Overweight Rating
Harvard Bioscience Is Maintained at Overweight by Keybanc
Harvard Bioscience Price Target Cut to $7.00/Share From $10.00 by Keybanc
Harvard Bioscience analyst ratings
Keybanc Maintains Overweight on Harvard Bioscience, Lowers Price Target to $7
Analysis
Price Target
No Data
